MedTrace Logo

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

NCT00850044 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2017-11-20

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetic and safety profiles of an experimental HCV protease inhibitor with and without ritonavir in healthy volunteers.

Conditions

  • HCV Infection

Interventions

DRUG

ABT-450

capsules,QD, one dose, see Arm Descriptions for more information

DRUG

ritonavir

capsules, QD, one dose, escalating doses, see Arm Descriptions for more information

DRUG

placebo for ABT-450

capsules, QD, one dose

DRUG

Placebo for ritonavir

capsules, QD, one dose

Sponsors & Collaborators

Principal Investigators

  • Adebayo A Lawal, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00850044 on ClinicalTrials.gov